Elevance Health Inc.ELVNYSE

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 75% recommend buying.

Consensus Rating

Buy

24 analysts·High coverage

75%

Rating Distribution

Strong Buy

00%

Buy

1875%

Hold

625%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 5% higher.

Bear Case

$320.00

-14%

Consensus

$391.00

+5%

Bull Case

$431.00

+16%

Price Range24 analysts

Low

Consensus

High

$320.00

$431.00

Current Target

Current Price

$370.68

Upside to Target

$20.32

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$26.79(15 analysts)

P/E15x

Current: 15.1x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+4.11%

EPS+16.14%

FY2028

Rev+1.74%

EPS+29.68%

FY2029

Rev+7.44%

EPS+20.81%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+2.4%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 9, 2026Mizuho Securities

Elevance Health price target raised to $413 from $400 at Mizuho

Target:$413.00

+10.2%from $374.77

Jan 8, 2026Wolfe Research

Elevance Health upgraded to Outperform from Peer Perform at Wolfe Research

Target:$425.00

+15.9%from $366.69

Jan 7, 2026Wells Fargo

Elevance Health price target raised to $424 from $403 at Wells Fargo

Target:$424.00

+14.2%from $371.37

Jan 6, 2026Bernstein

Elevance Health price target raised to $431 from $412 at Bernstein

Target:$431.00

+17.0%from $368.51

Jan 5, 2026Barclays

Elevance Health price target raised to $404 from $385 at Barclays

Target:$404.00

+14.0%from $354.25

Dec 19, 2025Deutsche Bank

Elevance Health downgraded to Hold from Buy at Deutsche Bank

Target:$320.00

-7.1%from $344.60

Dec 18, 2025Morgan Stanley

Elevance Health price target lowered to $352 from $359 at Morgan Stanley

Target:$352.00

+1.7%from $345.96

Nov 3, 2025Mizuho Securities

Elevance Health price target lowered to $400 from $420 at Mizuho

Target:$400.00

+27.7%from $313.19

Oct 22, 2025Barclays

Elevance Health price target lowered to $385 from $395 at Barclays

Target:$385.00

+13.0%from $340.76

Oct 21, 2025Bernstein

Bernstein SocGen Group Reiterates Outperform Rating on Elevance (ELV)

Target:$420.00

+20.5%from $348.48

Oct 14, 2025Truist Financial

Elevance Health price target raised to $400 from $365 at Truist

Target:$400.00

+14.9%from $348.16

Oct 14, 2025Morgan Stanley

Elevance Health price target raised to $359 from $316 at Morgan Stanley

Target:$359.00

+2.8%from $349.16

Oct 14, 2025Goldman Sachs

Elevance Health initiated with a Neutral at Goldman Sachs

Target:$343.00

-2.4%from $351.42

Oct 9, 2025Mizuho Securities

Elevance Health price target raised to $420 from $342 at Mizuho

Target:$420.00

+15.9%from $362.34

Oct 9, 2025Barclays

Elevance Health price target raised to $395 from $373 at Barclays

Target:$395.00

+9.0%from $362.34

Oct 8, 2025Guggenheim

Elevance Health price target raised to $398 from $360 at Guggenheim

Target:$398.00

+11.3%from $357.49

Oct 7, 2025Wells Fargo

Elevance Health price target raised to $412 from $330 at Wells Fargo

Target:$412.00

+17.7%from $349.94

Jun 9, 2025Truist Financial

Elevance Health price target lowered to $500 from $510 at Truist

Target:$500.00

+28.3%from $389.61

Apr 25, 2025Argus Research

Elevance Health price target raised to $465 from $450 at Argus

Target:$465.00

+10.3%from $421.68

Oct 21, 2024Jefferies

Elevance (ELV) PT Lowered to $529 at Jefferies

Target:$529.00

+22.8%from $430.77

Oct 21, 2024Leerink Partners

Elevance (ELV) PT Lowered to $515 at Leerink Partners

Target:$515.00

+19.6%from $430.77

Oct 18, 2024Raymond James

These Analysts Cut Their Forecasts On Elevance Health Following Q3 Earnings

Target:$485.00

+12.1%from $432.53

Oct 18, 2024RBC Capital

Elevance (ELV) PT Lowered to $478 at RBC Capital

Target:$478.00

+7.6%from $444.35

Oct 18, 2024Truist Financial

Elevance (ELV) PT Lowered to $520 at Truist Securities

Target:$520.00

+17.0%from $444.35

Oct 16, 2024Robert W. Baird

Baird Reiterates Outperform Rating on Elevance (ELV)

Target:$625.00

+29.2%from $483.87

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance